Trial Profile

Phase 1 study of KET-IR in healthy males and females

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketamine (Primary)
Indications Bipolar depression; Depression
Focus Adverse reactions; First in man
Sponsors Neurocentrx Pharma

Most Recent Events

30 Oct 2023 New trial record
24 Oct 2023 According to a Neurocentrx Pharma Media Release, the company is working with regulators on a clear development pathway to achieve commercial-scale manufacturing and marketing approval of KET-IR and a new ketamine formulation to treat depression in line with the USA FDA abuse deterrence guidelines.
24 Oct 2023 According to a Neurocentrx Pharma Media Release, the company sponsored the study in part via Innovator Award funding from the Wellcome Trust.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com